The immunotherpay can give children and adults three extra years before they need to use insulin.

England becomes the first European country to roll out Teplizumab, shifting type 1 diabetes care from treatment to disease ...

The U.S. Food and Drug Administration has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) to delay the ...

Teplizumab is the disease-modifying therapy for type 1 diabetes and England is the first country in Europe to recommend it's use through a health technology appraisal.

Teplizumab is an immunotherapy drug designed to modify the immune system's response. Instead of simply treating symptoms, it ...

The National Institute for Health and Care Excellence (Nice) has approved teplizumab, with Diabetes UK saying it 'marks the ...

A TYPE 1 diabetes drug about to be offered on the NHS is the biggest medical breakthrough against the condition since insulin ...

The biologic is the first drug that aims to delay the diagnosis of type 1 diabetes. The FDA Thursday approved teplizumab, the first drug to delay the onset of type 1 diabetes (T1D). Teplizumab, a ...

Add Yahoo as a preferred source to see more of our stories on Google. During the 2026 American Diabetes Association (ECO) Scientific Sessions in New Orleans, a real-world cohort of type 1 diabetic ...

A disease modifying therapy that can delay the onset of type 1 diabetes for up to three years has been recommended for use on ...

A first-of-its-kind therapy that can delay the onset of type 1 diabetes for up to three years has been approved for use by ...

Teplizumab is used to delay the onset of stage 3 type 1 diabetes in children aged 8 years and older, and adults, with stage 2 ...